Skip to main content

Shock, Septic

3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
EsmololPhase 2/3Small Molecule1 trial
Active Trials
NCT02842983Unknown36Est. Dec 2016
Inotrem
InotremFrance - Paris
2 programs
2
Nangibotide 0.3 mg/kgPhase 21 trial
nangibotide low dosePhase 21 trial
Active Trials
NCT03158948Completed50Est. Jun 2018
NCT04055909Active Not Recruiting355Est. May 2023
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
PhysostigmineN/A1 trial
Active Trials
NCT03013322Completed20Est. Feb 2017
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
SevofluranePHASE_21 trial
Active Trials
NCT03643367Not Yet RecruitingEst. Nov 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
UNION therapeuticsEsmolol
City TherapeuticsSevoflurane
Inotremnangibotide low dose
InotremNangibotide 0.3 mg/kg
Heidelberg PharmaPhysostigmine

Clinical Trials (5)

Total enrollment: 461 patients across 5 trials

NCT02842983UNION therapeuticsEsmolol

Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients

Start: Dec 2014Est. completion: Dec 201636 patients
Phase 2/3Unknown
NCT03643367City TherapeuticsSevoflurane

Sevoflurane Sedation in Patients With Septic Shock

Start: Jan 2026Est. completion: Nov 2027
Phase 2Not Yet Recruiting
NCT04055909Inotremnangibotide low dose

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock

Start: Nov 2019Est. completion: May 2023355 patients
Phase 2Active Not Recruiting
NCT03158948InotremNangibotide 0.3 mg/kg

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock

Start: Jul 2017Est. completion: Jun 201850 patients
Phase 2Completed
NCT03013322Heidelberg PharmaPhysostigmine

Anticholium® Per Se

Start: Jan 2015Est. completion: Feb 201720 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.